GS-493
Based on 1 publication(s) in Google Scholar
GS-493 is a selective protein tyrosine phosphatase SHP2 (PTPN11) inhibitor with an IC50 of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 1710337-31-7
- Formula: C21H14N6O8S
- Molecular Weight:510.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) GS-493
More
Biological Activity
IC50: 71 nM (SHP2); 2.08 μM (SHP1); 3.17 μM (PTP1B)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HPAF-II | IC50 |
3.4 μM
Compound: 3; GS493
|
Inhibition of HGF-induced cell scattering in human HPAF-II cells incubated for 1 hr by Hoechst staining based assay
Inhibition of HGF-induced cell scattering in human HPAF-II cells incubated for 1 hr by Hoechst staining based assay
|
[PMID: 33210922] |
GS-493 (0.0625-10 μM) blocks hepatocyte growth factor (HGF)-stimulated epithelial-mesenchymal transition of human pancreatic adenocarcinoma (HPAF) cells[1].
GS-493 (40 μM, a couple of days) blocks growth of the human NSCL cancer cell line LXFA 526L in soft agar and decreases the number of tumor cell colonies to 32%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mouse xenograft model (strain NMRI nu/nu mice)
-
Dosage:46 mg/kg (45.93 mg in 3 mL DMSO per kg)
-
Administration:i.p.; daily for 27 days
-
Result:Inhibited tumor growth significantly.
Chemical Information
-
CAS No. 1710337-31-7
-
Molecular Weight 510.44
-
Formula C21H14N6O8S
-
SMILES
O=S(C1=CC=C(N/N=C2C(C3=CC=C([N+]([O-])=O)C=C3)=NN(C4=CC=C([N+]([O-])=O)C=C4)C/2=O)C=C1)(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
Clarithromycin-treated chronic spontaneous urticaria with the negative regulation of FcεRΙ and MRGPRX2 activation via CD300f. [Abstract]2022 Sep:110:109063. PMID: 35853276
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)